These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37244515)

  • 1. The Heart Failure Knights.
    Mozzini C; Pagani M
    Curr Probl Cardiol; 2023 Sep; 48(9):101834. PubMed ID: 37244515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond.
    Morelli C; Ingrasciotta G; Jacoby D; Masri A; Olivotto I
    Eur J Intern Med; 2022 Aug; 102():1-7. PubMed ID: 35534374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A year in heart failure: an update of recent findings.
    Stretti L; Zippo D; Coats AJS; Anker MS; von Haehling S; Metra M; Tomasoni D
    ESC Heart Fail; 2021 Dec; 8(6):4370-4393. PubMed ID: 34918477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines.
    Tsutsui H
    Pharmacol Ther; 2022 Oct; 238():108185. PubMed ID: 35413307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?
    Ameri P; Bertero E; Maack C; Teerlink JR; Rosano G; Metra M
    Eur Heart J Cardiovasc Pharmacother; 2021 Nov; 7(6):539-546. PubMed ID: 34037742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology.
    Mullens W; Martens P; Testani JM; Tang WHW; Skouri H; Verbrugge FH; Fudim M; Iacoviello M; Franke J; Flammer AJ; Palazzuoli A; Barragan PM; Thum T; Marcos MC; Miró Ò; Rossignol P; Metra M; Lassus J; Orso F; Jankowska EA; Chioncel O; Milicic D; Hill L; Seferovic P; Rosano G; Coats A; Damman K
    Eur J Heart Fail; 2022 Apr; 24(4):603-619. PubMed ID: 35239201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
    Lewis GD; Voors AA; Cohen-Solal A; Metra M; Whellan DJ; Ezekowitz JA; Böhm M; Teerlink JR; Docherty KF; Lopes RD; Divanji PH; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Felker GM
    JAMA; 2022 Jul; 328(3):259-269. PubMed ID: 35852527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus statement on the current pharmacological prevention and management of heart failure.
    Sindone AP; De Pasquale C; Amerena J; Burdeniuk C; Chan A; Coats A; Hare DL; Macdonald P; Sverdlov A; Atherton JJ
    Med J Aust; 2022 Aug; 217(4):212-217. PubMed ID: 35908234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in contemporary medical management to treat patients with heart failure.
    Velez M
    Curr Opin Cardiol; 2023 Mar; 38(2):136-142. PubMed ID: 36718623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Legg JC; Büchele G; Varin C; Kurtz CE; Malik FI; Honarpour N
    JACC Heart Fail; 2020 Apr; 8(4):329-340. PubMed ID: 32035892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy.
    Rahamim E; Nachman D; Yagel O; Yarkoni M; Elbaz-Greener G; Amir O; Asleh R
    J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update.
    Hellenkamp K; Nolte K; von Haehling S
    Expert Opin Pharmacother; 2022 Apr; 23(6):673-680. PubMed ID: 35260016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
    JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction.
    McDonald M; Virani S; Chan M; Ducharme A; Ezekowitz JA; Giannetti N; Heckman GA; Howlett JG; Koshman SL; Lepage S; Mielniczuk L; Moe GW; O'Meara E; Swiggum E; Toma M; Zieroth S; Anderson K; Bray SA; Clarke B; Cohen-Solal A; D'Astous M; Davis M; De S; Grant ADM; Grzeslo A; Heshka J; Keen S; Kouz S; Lee D; Masoudi FA; McKelvie R; Parent MC; Poon S; Rajda M; Sharma A; Siatecki K; Storm K; Sussex B; Van Spall H; Yip AMC
    Can J Cardiol; 2021 Apr; 37(4):531-546. PubMed ID: 33827756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management.
    Patel PH; Nguyen M; Rodriguez R; Surani S; Udeani G
    Cureus; 2021 Jan; 13(1):e12419. PubMed ID: 33542867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial.
    Felker GM; Solomon SD; Claggett B; Diaz R; McMurray JJV; Metra M; Anand I; Crespo-Leiro MG; Dahlström U; Goncalvesova E; Howlett JG; MacDonald P; Parkhomenko A; Tomcsányi J; Abbasi SA; Heitner SB; Hucko T; Kupfer S; Malik FI; Teerlink JR
    JAMA Cardiol; 2022 Jan; 7(1):26-34. PubMed ID: 34643642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Adams KF; Anand I; Arias-Mendoza A; Biering-Sørensen T; Böhm M; Bonderman D; Cleland JGF; Corbalan R; Crespo-Leiro MG; Dahlström U; Echeverria Correa LE; Fang JC; Filippatos G; Fonseca C; Goncalvesova E; Goudev AR; Howlett JG; Lanfear DE; Lund M; Macdonald P; Mareev V; Momomura SI; O'Meara E; Parkhomenko A; Ponikowski P; Ramires FJA; Serpytis P; Sliwa K; Spinar J; Suter TM; Tomcsanyi J; Vandekerckhove H; Vinereanu D; Voors AA; Yilmaz MB; Zannad F; Sharpsten L; Legg JC; Abbasi SA; Varin C; Malik FI; Kurtz CE;
    Eur J Heart Fail; 2020 Nov; 22(11):2160-2171. PubMed ID: 32985088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying the patient with heart failure to be treated with vericiguat.
    Escobar Cervantes C; Esteban Fernández A; Recio Mayoral A; Mirabet S; González Costello J; Rubio Gracia J; Núñez Villota J; González Franco Á; Bonilla Palomas JL
    Curr Med Res Opin; 2023 May; 39(5):661-669. PubMed ID: 36897009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 'diamond' approach to personalized drug treatment of heart failure with reduced ejection fraction.
    Gan H; Tang H; Huang Y; Wang D; Pu P; Zuo Z
    Rev Cardiovasc Med; 2021 Sep; 22(3):573-584. PubMed ID: 34565061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.